COR Cencora, Inc. Common Stock
Cencora, Inc. Common Stock 정보 위키백과 회사 개요
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area.
더 보기
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area.
Background
AmerisourceBergen was formed in 2001 following the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. David Yost was CEO of Amerisource prior to the merger and remained in the position after the companies merged.
AmerisourceBergen has 26 pharmaceutical distribution centers in the US, nine distribution centers in Canada, four specialty distribution centers in the US, and over 1 million square feet of packaging production capacity in the US and the UK. With the addition of World Courier, the largest specialty courier company in the world, over 150 company-owned offices around the globe were added to the company.
AmerisourceBergen operates its pharmaceutical distribution business under four primary units: AmerisourceBergen Drug Corporation (ABDC), AmerisourceBergen Specialty Group (ABSG), AmerisourceBergen Consulting Services (ABCS) and World Courier. In March 2016, pharmacy Walgreens Boots Alliance Inc. announced it would exercise an option to purchase 22.7 million shares of AmerisourceBergen stock and thereby control 15% of the company.
In 2012, the firm was the largest by revenue based in Pennsylvania. The company changed its name to Cencora as of August 30, 2023 and began trading on the New York Stock Exchange under the new ticker symbol "COR". In May 2024, Cencora disclosed it had been the subject of a cyber incident in which patient information was exposed.
Products
They provide drug distribution and consulting related to medical business operations and patient services. They also distribute a line of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to health care providers throughout the United States, including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics and other alternate site facilities, as well as nursing and assisted living centers. They also provide pharmaceuticals and pharmacy services to long-term care, workers' compensation and specialty drug patients.
AmerisourceBergen handles about 20% of all of the pharmaceuticals sold and distributed throughout the United States and ranked 10th on the Fortune 500 list for 2020 with over $179 billion in annual revenue.
Good Neighbor Pharmacy
Good Neighbor Pharmacy is an American retailers' cooperative network of more than 3,400 independently owned and operated pharmacies. It has a business affiliation with AmerisourceBergen, which sponsors the network and owns the name "Good Neighbor Pharmacy." Good Neighbor Pharmacy is the sponsor for "ThoughtSpot," the annual trade show held in both Orlando and Las Vegas.
Acquisition history
In 2011, the company acquired IntrinsiQ for $35 million and Premier Source for an undisclosed amount. In July, Steven Collis replaced Yost as CEO of the company.
In March 2012, AmerisourceBergen agreed to acquire World Courier Group Inc, a transportation and logistics provider for the biopharmaceutical industry, for $520 million.
In January 2015, the company bought MWI Veterinary for $2.5 billion. In October, they agreed to buy PharMEDium, a compounding drug company, for $2.58 billion.
On January 3, 2018, AmerisourceBergen acquired H. D. Smith, the largest privately held national pharmaceutical wholesaler in the U.S.
On June 2, 2021, AmerisourceBergen acquired Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion, made up of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock.
On January 2, 2025, Cencora acquired 85% of Retina Consultants of America for approximately $4.4 billion.
Distribution of Remdesivir
In June 2020, the U.S. Department of Health and Human Services (HHS) announced an unusual agreement for the distribution of remdesivir, the first coronavirus drug. HHS agreed to manufacturer Gilead's wholesale acquisition price, while HHS would continue to work together with state governments and AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that time-frame American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses.
Finances
For the fiscal year 2019, AmerisourceBergen reported earnings of US$1.11 billion, with an annual revenue of US$179.58 billion. AmerisourceBergen's shares traded at over $88 per share, and its market capitalization was valued at over US$19.2 billion in September 2019.
Controversies
Opioid epidemic
AmerisourceBergen is among several distributors that have been sued by West Virginia for contributing to the opioid epidemic in the United States, by shipping inordinate amounts of pain medication into the state.
In December 2019, Michigan became the first state to sue AmerisourceBergen and three other opioid distributors as drug dealers for their role in the state's opioid crisis. The lawsuit is filed under the Michigan Drug Dealer Liability Act. AmerisourceBergen was among four companies who, because of their role in the addiction crisis, agreed to pay $260 million to two Ohio counties. In May 2020, Oklahoma Attorney General Mike Hunter sued AmerisourceBergen in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against Cardinal Health and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets." In January 2022, AmerisourceBergen, McKesson, Cardinal Health, and Johnson & Johnson agreed to pay $26 billion to settle with all but five of the states suing them. The deal covered the bulk of the grievances against these four companies, including 90 percent of municipal governments, 46 states, and Washington, DC. Had the states gone to court, the companies could have faced up to $95 billion in penalties. AmerisourceBergen and the three other companies did not admit wrongdoing.
Legal issues
In October 2018, AmerisourceBergen agreed to pay $625 million to settle civil fraud allegations resulting from its repackaging and sale of adulterated drugs and unapproved new drugs, double billing and providing kickbacks to physicians. The company had previously been found guilty of a misdemeanor charge related to the repackaging and distribution of pre-filled syringes that lacked FDA approval. In connection with this case, AmerisourceBergen agreed to pay $260 million, bringing the total settlement amount to $885 million.
As part of the civil settlement, ABC admitted that between January 2001 and January 2014, MII and OSC operated a program that created, packed and shipped millions of pre-filled syringes (PFS) to oncology practices for administration to vulnerable cancer patients (the PFS Program). At MII, an ABC subsidiary located in Alabama, the drug product was removed from the original glass vials and multiple vials of the product were pooled in untested plastic containers. Then the drug, including the overfill, was extracted and repackaged into syringes. By harvesting the overfill, ABC was able to create more doses than it bought from the original vial manufacturers and avoid opening some of the vials. ABC retained the unopened vials and sold them to other customers and to its subsidiary ABDC for resale. During the 13 years the PFS Program was in operation, MII manufactured thousands of syringes daily, and eventually over one million syringes per year. These syringes were sold throughout the United States. Approximately 57% of the patients who were injected with the PFS were Federal Health Care Program beneficiaries. The profit from the PFS Program was between $2.3 and $14.4 million annually for a total profit of at least $99.6 million.
ABC’s scheme enabled it to bill multiple health care providers for the same vial of drug, causing some of those providers to bill the Federal Health Care Programs for the same vial more than once. The scheme also enabled ABC to increase its market share by offering various product discounts, which it leveraged to obtain new customers and to keep existing customers who purchased its entire portfolio of oncology drugs. ABC excluded the entire PFS Program from its standard regulatory audit and pedigree compliance programs. AmerisourceBergen's stock price reportedly plummeted after they were among other drug distributors who offered $10 billion to settle their portion of the national opioids lawsuit. States countered with $45 billion.
In 2022, the United States government filed a lawsuit against AmerisourceBergen for contributing to the opioid crisis in America. The suit, which was filed by the United States Department of Justice with federal prosecutors in New Jersey, Colorado, Pennsylvania, and New York, alleged that the company distributed opioids that were later resold illegally.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
COR 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
COR 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 |
|---|---|
| 2026년 5월 15일 | $0.6000 |
| 2026년 2월 13일 | $0.6000 |
| 2025년 11월 14일 | $0.6000 |
| 2025년 8월 15일 | $0.5500 |
| 2025년 5월 16일 | $0.5500 |
| 2025년 2월 14일 | $0.5500 |
| 2024년 11월 15일 | $0.5500 |
| 2024년 8월 9일 | $0.5100 |
| 2024년 5월 9일 | $0.5100 |
| 2024년 2월 8일 | $0.5100 |
| 2023년 11월 10일 | $0.5100 |
| 2023년 8월 10일 | $0.4850 |
| 2023년 5월 11일 | $0.4850 |
| 2023년 2월 9일 | $0.4850 |
| 2022년 11월 10일 | $0.4850 |
| 2022년 8월 12일 | $0.4600 |
| 2022년 5월 13일 | $0.4600 |
| 2022년 2월 11일 | $0.4600 |
| 2021년 12월 1일 | $1.2700 |
| 2021년 11월 12일 | $0.4600 |
COR 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 5 25.0%
- 매수 10 50.0%
- 보유 5 25.0%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
12 명의 애널리스트 · 2026-08-13실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 9월 30일 | $4.48 | $4.39 | 0.09% |
| 2026년 6월 30일 | $4.48 | $4.39 | 0.09% |
| 2026년 3월 31일 | $4.75 | $4.86 | -0.11% |
| 2025년 12월 31일 | $4.08 | $4.08 | 0.00% |
| 2025년 9월 30일 | $3.84 | $3.82 | 0.02% |
| 2025년 6월 30일 | $4.00 | $3.88 | 0.12% |
| 2025년 3월 31일 | $4.42 | $4.15 | 0.27% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| COR | $60.61B | 39.3 | 9.3% | 0.48% | 144.3% | 3.6% |
| MCK | $242.30B | 22.5 | 12.4% | 1.2% | -224.3% | 3.6% |
| CAH | — | 32.9 | 14.2% | 0.67% | -60.5% | 3.8% |
| HSIC | $8.81B | 23.3 | 4.0% | 3.0% | 12.0% | 31.1% |
| AHCO | $1.35B | -19.2 | -0.49% | -2.2% | -4.6% | — |
| ACH | — | — | — | — | — | — |
| MEDS | — | — | — | — | — | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 15
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B | $153.14B | $146.85B | $135.96B | $119.57B | |
| Cost of Revenue | $309.85B | $284.05B | $253.21B | $230.29B | $207.05B | $184.70B | $174.45B | $163.33B | $148.60B | $142.58B | $132.43B | $116.59B | |
| Gross Profit | $11.48B | $9.91B | $8.96B | $8.30B | $6.94B | $5.19B | $5.14B | $4.61B | $4.55B | $4.27B | $3.53B | $2.98B | |
| SG&A Expense | $6.49B | $5.66B | $5.31B | $4.85B | $3.59B | $2.77B | $2.66B | $2.46B | $2.13B | $2.09B | $1.91B | $1.58B | |
| Operating Expenses | $6.99B | $6.09B | $5.72B | · | · | · | · | · | · | · | · | · | |
| Operating Income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B | $-5.14B | $1.11B | $1.44B | $1.06B | $1.53B | $422M | $782M | |
| Other Non-op | $-79M | $-14M | $49M | $27M | $42M | $2M | $13M | $-25M | $3M | $5M | $-14M | $4M | |
| Pretax Income | $2.26B | $2.00B | $2.16B | $2.18B | $2.22B | $-5.29B | $967M | $1.18B | $918M | $1.39B | $269M | $670M | |
| Income Tax | $691M | $485M | $428M | $517M | $677M | $-1.89B | $113M | $-438M | $553M | $-37M | $407M | $388M | |
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | $-3.41B | $855M | $1.66B | $364M | $1.43B | $-138M | $274M | |
| EPS (Basic) | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 | $-16.65 | $4.07 | $7.61 | $1.67 | $6.73 | $-0.63 | $1.21 | |
| EPS (Diluted) | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | $-16.65 | $4.04 | $7.53 | $1.64 | $6.32 | $-0.63 | $1.16 | |
| Shares (Basic) | 193,820,000 | 198,503,000 | 202,511,000 | 208,472,000 | 205,919,000 | 204,783,000 | 210,165,000 | 217,872,000 | 218,375,000 | 212,206,000 | 217,786,000 | 227,367,000 | |
| Shares (Diluted) | 195,214,000 | 200,284,000 | 204,591,000 | 211,210,000 | 208,465,000 | 204,783,000 | 211,840,000 | 220,336,000 | 221,602,000 | 225,959,000 | 217,786,000 | 235,405,000 | |
| EBITDA | $3.68B | $3.27B | $3.30B | $3.06B | $2.86B | $-4.74B | $1.57B | $1.91B | $1.46B | $1.89B | $661M | $964M |
대차대조표 29
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.36B | $3.13B | $2.59B | $3.39B | $2.55B | $4.60B | $3.37B | $2.49B | $2.44B | $2.74B | $2.17B | $1.81B | |
| Receivables | $25.23B | $23.87B | $20.91B | $18.45B | $18.17B | $13.85B | $12.39B | $11.31B | $10.30B | $9.18B | $8.22B | $6.31B | |
| Inventory | $20.49B | $19.00B | $17.45B | $15.56B | $15.37B | $12.59B | $11.06B | $11.92B | $11.46B | $10.72B | $9.76B | $8.59B | |
| Prepaid Expense | $539M | $539M | $449M | $488M | $854M | $189M | $157M | $169M | $103M | $210M | $189M | $85M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $85M | |
| Current Assets | $52.24B | $47.72B | $42.80B | $39.59B | $38.80B | $33.06B | $28.13B | $25.89B | $24.30B | $22.85B | $20.33B | $16.80B | |
| PP&E (Net) | $2.54B | $2.18B | $2.14B | $2.14B | $2.16B | $1.48B | $1.77B | $1.89B | $1.80B | $1.53B | $1.19B | $900M | |
| PP&E (Gross) | $5.73B | $5.22B | $4.74B | $4.39B | $4.08B | $3.24B | $3.35B | $3.41B | $3.09B | $2.62B | $2.14B | $1.69B | |
| Accum. Depreciation | $3.19B | $3.03B | $2.60B | $2.25B | $1.92B | $1.76B | $1.58B | $1.52B | $1.29B | $1.09B | $950M | $793M | |
| Goodwill | $13.68B | $9.32B | $9.57B | $8.50B | $9.03B | $6.71B | $6.71B | $6.66B | $6.04B | $5.99B | $4.14B | $2.95B | |
| Intangibles | $3.77B | $4.00B | $4.43B | $4.33B | $5.26B | $1.89B | $2.29B | $2.95B | $2.83B | $2.97B | $1.99B | $533M | |
| Other Non-current Assets | $4.15B | $3.64B | $3.42B | $1.76B | $1.79B | $780M | $269M | $271M | $338M | $296M | $298M | $351M | |
| Total Assets | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B | $39.17B | $37.67B | $35.32B | $33.64B | $27.96B | $21.53B | |
| Accounts Payable | $54.72B | $50.94B | $45.84B | $40.19B | $38.01B | $31.71B | $28.39B | $26.84B | $25.40B | $23.93B | $20.89B | $15.59B | |
| Accrued Liabilities | $2.98B | $2.76B | $2.35B | $2.21B | $2.86B | $1.65B | $1.06B | $881M | $1.40B | $744M | $692M | $562M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Current Liabilities | $57.82B | $54.28B | $48.83B | $43.48B | $41.36B | $33.85B | $29.58B | $27.87B | $26.82B | $25.28B | $21.58B | $17.25B | |
| Capital Leases | $1.42B | $1.03B | $924M | $864M | $946M | $386M | $321M | $352M | $352M | $276M | $246M | · | |
| Deferred Tax | $1.62B | $1.64B | $1.66B | $1.62B | $1.69B | $686M | $1.86B | $1.83B | $2.49B | $2.21B | $1.94B | $241M | |
| Other Non-current Liabilities | $3.64B | $1.99B | $1.88B | $977M | $1.08B | $473M | $99M | $110M | $75M | $160M | $85M | $88M | |
| Long-term Debt | $7.66B | $4.39B | $4.79B | $5.70B | $6.68B | $4.12B | $4.17B | $177M | $3.44B | $4.19B | $3.49B | $2.00B | |
| Total Debt | $7.54B | $3.81B | $4.15B | $4.63B | $6.38B | $3.62B | $4.03B | $4.17B | $3.43B | $3.59B | $3.49B | $2.00B | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Retained Earnings | $6.53B | $5.42B | $4.32B | $2.98B | $1.67B | $518M | $4.24B | $3.72B | $2.40B | $2.30B | $1.16B | $1.57B | |
| Treasury Stock | $10.33B | $9.82B | $8.25B | $7.02B | $6.47B | $6.51B | $6.10B | $5.43B | $4.76B | $4.40B | $4.15B | $2.31B | |
| AOCI | $-901M | $-989M | $-1.40B | $-1.83B | $-445M | $-109M | $-112M | $-79M | $-96M | $-114M | $-136M | $-52M | |
| Stockholders' Equity | $1.51B | $646M | $522M | $-212M | $223M | $-1.02B | $2.88B | $2.93B | $2.06B | $2.13B | $616M | $1.94B | |
| Liabilities + Equity | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B | $39.17B | $37.67B | $35.32B | $33.64B | $27.96B | $21.53B | |
| Shares Outstanding | 193,937,673 | 194,943,968 | 200,814,804 | 206,203,817 | 208,089,298 | 204,226,465 | 206,760,654 | 213,217,882 | 217,993,598 | 220,050,502 | 206,891,873 | 221,908,650 |
현금 흐름 19
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.05B | $1.09B | $964M | $694M | $505M | $391M | $462M | $465M | $398M | $365M | $249M | $189M | |
| Stock-based Comp | $148M | $148M | $125M | $93M | $100M | $74M | $59M | $62M | $62M | $65M | $61M | $43M | |
| Deferred Tax | $60M | $-102M | $-119M | $196M | $335M | $-1.54B | $29M | $-796M | $319M | $-131M | $21M | $38M | |
| Amort. of Intangibles | $557M | $663M | $554M | $307M | $178M | $111M | $167M | $181M | $161M | $152M | $56M | $26M | |
| Restructuring | $229M | $234M | $230M | $63M | $82M | $6.81B | $330M | $184M | $959M | $103M | $38M | $8M | |
| Other Non-cash | $1.06B | $838M | $1.20B | $21M | $187M | $6.70B | $939M | $21M | $361M | $1.45B | $3.73B | $919M | |
| Operating Cash Flow | $3.88B | $3.48B | $3.91B | $2.70B | $2.67B | $2.21B | $2.34B | $1.41B | $1.50B | $3.18B | $3.92B | $1.46B | |
| CapEx | $668M | $487M | $458M | $496M | $438M | $370M | $310M | $336M | $466M | $465M | $232M | $264M | |
| Investing Cash Flow | $-4.98B | $-618M | $-2.60B | $-368M | $-6.14B | $-380M | $-376M | $-1.11B | $-498M | $-3.17B | $-2.93B | $-384M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $1.10B | |
| Net Debt Issued | $-1.28B | · | · | · | $-835M | $-598M | $-511M | $-681M | $-750M | $-800M | $-500M | $566M | |
| Stock Issued | · | · | · | $0 | $0 | $66M | $0 | $0 | · | · | · | · | |
| Stock Repurchased | $435M | $1.49B | $1.18B | $484M | $82M | $420M | $674M | $639M | $330M | $2.27B | $1.86B | $754M | |
| Net Stock Activity | $-435M | $-1.49B | $-1.18B | $-484M | $-82M | $-354M | $-674M | $-639M | $-330M | $-2.27B | $-1.86B | $-754M | |
| Dividends Paid | $437M | $416M | $399M | $392M | $367M | $344M | $339M | $333M | $320M | $288M | $254M | $214M | |
| Financing Cash Flow | $2.25B | $-2.33B | $-2.22B | $-1.75B | $1.95B | $-604M | $-1.09B | $-243M | $-1.31B | $565M | $-632M | $-503M | |
| Net Change in Cash | $1.10B | $545M | $-841M | $523M | $-1.53B | $1.22B | $882M | $57M | $-307M | $574M | $359M | $578M | |
| Taxes Paid | $571M | $604M | $463M | $244M | $94M | $139M | $118M | $104M | $105M | $18M | $300M | $197M | |
| Free Cash Flow | $3.21B | $3.00B | $3.45B | $2.21B | $2.23B | $1.84B | $2.03B | $1.07B | $1.04B | $2.71B | $3.69B | $1.20B |
수익성 8
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.6% | 3.4% | 3.4% | 3.5% | 3.2% | 2.7% | 2.9% | 2.8% | 3.0% | 2.9% | 2.6% | 2.5% | |
| Operating Margin | 0.82% | 0.74% | 0.89% | 0.99% | 1.1% | -2.7% | 0.62% | 0.86% | 0.69% | 1.0% | 0.31% | 0.65% | |
| Net Margin | 0.48% | 0.51% | 0.67% | 0.71% | 0.72% | -1.8% | 0.48% | 0.99% | 0.24% | 0.97% | -0.10% | 0.23% | |
| Pretax Margin | 0.70% | 0.68% | 0.82% | 0.91% | 1.0% | -2.8% | 0.54% | 0.70% | 0.60% | 0.95% | 0.20% | 0.56% | |
| EBITDA Margin | 1.1% | 1.1% | 1.3% | 1.3% | 1.3% | -2.5% | 0.88% | 1.1% | 0.95% | 1.3% | 0.49% | 0.81% | |
| ROA | 2.2% | 2.3% | 2.9% | 3.0% | 3.0% | -8.2% | 2.2% | 4.5% | 1.1% | 4.6% | -0.55% | 1.4% | |
| ROE | 144.3% | 258.4% | 1124.4% | 28805.8% | -387.1% | -366.5% | 29.4% | 66.4% | 17.4% | 104.0% | -10.5% | 13.0% | |
| ROIC | 20.2% | 37.0% | 40.2% | 40.9% | 24.8% | -126.9% | 14.2% | 27.9% | 7.7% | 27.4% | -5.0% | 8.3% |
유동성 및 지급능력 4
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | |
| Quick Ratio | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
| Debt / Equity | 5.0 | 5.9 | 7.9 | -21.9 | 28.6 | -3.6 | 1.4 | 1.4 | 1.7 | 1.7 | 5.5 | 1.0 | |
| LT Debt / Equity | 5.0 | 5.9 | 7.9 | -21.9 | 28.6 | -3.6 | 1.4 | 1.4 | 1.7 | 1.7 | 5.5 | 1.0 |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.5 | 4.5 | 4.4 | 4.2 | 4.2 | 4.6 | 4.7 | 4.6 | 4.4 | 4.8 | 5.5 | 5.9 | |
| Inventory Turnover | 15.7 | 15.6 | 15.3 | 14.9 | 14.8 | 15.6 | 15.2 | 14.0 | 13.4 | 13.9 | 14.4 | 15.0 | |
| Receivables Turnover | 13.1 | 13.1 | 13.3 | 13.0 | 13.4 | 14.5 | 15.2 | 15.5 | 15.7 | 16.9 | 18.7 | 19.3 |
성장률 8
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.3% | 12.1% | 9.9% | 11.5% | 12.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.4% | 11.2% | 11.3% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.1% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 5.7% | -11.7% | 6.1% | 8.8% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -0.33% | 0.63% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 3.0% | -13.5% | 2.7% | 10.3% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -2.9% | -0.67% | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.9% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B | $153.14B | $146.85B | $135.96B | $119.57B | |
| Net Income TTM | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | $-3.41B | $855M | $1.66B | $364M | $1.43B | $-138M | $274M | |
| Market Cap | $60.61B | $43.88B | $36.14B | $27.91B | $24.86B | $19.79B | $17.02B | $19.66B | $18.04B | $17.78B | $19.65B | $17.15B | |
| Enterprise Value | $63.80B | $44.56B | $37.69B | $29.15B | $28.69B | $18.81B | $17.68B | $21.34B | $19.03B | $18.63B | $20.98B | $17.34B | |
| P/E | 39.3 | 29.9 | 21.1 | 16.8 | 16.2 | -5.8 | 20.4 | 12.2 | 50.5 | 12.8 | -150.8 | 66.6 | |
| P/S | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| P/B | 40.2 | 67.9 | 69.2 | -131.9 | 111.3 | -19.4 | 5.9 | 6.7 | 8.7 | 8.3 | 31.0 | 8.8 | |
| P / Cash Flow | 15.6 | 12.6 | 9.2 | 10.3 | 9.3 | 9.0 | 7.3 | 13.9 | 12.0 | 5.6 | 5.0 | 11.7 | |
| P / FCF | 18.9 | 14.6 | 10.5 | 12.6 | 11.2 | 10.8 | 8.4 | 18.3 | 17.4 | 6.5 | 5.3 | 14.3 | |
| EV / EBITDA | 17.3 | 13.6 | 11.4 | 9.5 | 10.0 | -4.0 | 11.2 | 11.2 | 13.1 | 9.9 | 31.8 | 18.0 | |
| EV / FCF | 19.9 | 14.9 | 10.9 | 13.2 | 12.9 | 10.2 | 8.7 | 19.9 | 18.3 | 6.9 | 5.7 | 14.5 | |
| EV / Revenue | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | |
| Dividend Yield | 0.72% | 0.95% | 1.1% | 1.4% | 1.5% | 1.7% | 2.0% | 1.7% | 1.8% | 1.6% | 1.3% | 1.2% | |
| Earnings Yield | 2.5% | 3.4% | 4.7% | 5.9% | 6.2% | -17.2% | 4.9% | 8.2% | 2.0% | 7.8% | -0.66% | 1.5% | |
| Payout Ratio | 28.1% | 27.6% | 22.9% | 23.1% | 23.8% | -10.1% | 39.6% | 20.1% | 87.9% | 20.2% | -188.2% | 77.6% | |
| Annual Payout | $437M | $416M | $399M | $392M | $367M | $344M | $339M | $333M | $320M | $288M | $254M | $214M |
손익계산서 15
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84.75B | $78.36B | $85.93B | $83.73B | $80.66B | $75.45B | $81.49B | $79.05B | $74.24B | $68.41B | $72.25B | $68.92B | $66.95B | $63.46B | $62.85B | $61.17B | |
| Cost of Revenue | $81.15B | $74.77B | $82.86B | $80.77B | $77.76B | $72.39B | $78.93B | $76.56B | $71.83B | $65.88B | $69.78B | $66.67B | $64.68B | $61.16B | $60.70B | $59.19B | |
| Gross Profit | $3.61B | $3.59B | $3.07B | $2.95B | $2.91B | $3.06B | $2.56B | $2.49B | $2.41B | $2.54B | $2.47B | $2.25B | $2.26B | $2.30B | $2.15B | $1.99B | |
| SG&A Expense | $2.13B | $1.98B | $1.80B | $1.75B | $1.67B | $1.60B | $1.47B | $1.49B | $1.38B | $1.39B | $1.40B | $1.39B | $1.30B | $1.32B | $1.29B | $1.26B | |
| Operating Expenses | $2.28B | $2.11B | $1.93B | $1.88B | $1.80B | $1.72B | $1.59B | · | · | · | · | · | · | · | · | · | |
| Operating Income | $1.12B | $1.14B | $760M | $19M | $868M | $1.04B | $706M | $127M | $672M | $553M | $823M | $477M | $670M | $561M | $633M | $455M | |
| Other Non-op | $17M | $1.09B | $21M | $-128M | $110M | $-4M | $-58M | $20M | $-13M | $-22M | $1M | $30M | $-3M | $16M | $6M | $-21M | |
| Pretax Income | $996M | $2.09B | $709M | $-187M | $896M | $929M | $620M | $125M | $628M | $467M | $783M | $446M | $609M | $512M | $593M | $382M | |
| Income Tax | $220M | $459M | $143M | $146M | $207M | $211M | $127M | $118M | $141M | $46M | $180M | $97M | $130M | $84M | $117M | $84M | |
| Net Income | $764M | $1.64B | $560M | $-340M | $687M | $718M | $489M | $3M | $483M | $421M | $602M | $351M | $480M | $435M | $480M | $295M | |
| EPS (Basic) | $3.95 | $8.44 | $2.88 | $-1.75 | $3.55 | $3.70 | $2.52 | $0.04 | $2.44 | $2.11 | $3.01 | $1.75 | $2.37 | $2.15 | $2.35 | $1.43 | |
| EPS (Diluted) | $3.94 | $8.40 | $2.87 | $-1.74 | $3.52 | $3.68 | $2.50 | $0.04 | $2.42 | $2.09 | $2.98 | $1.72 | $2.35 | $2.13 | $2.33 | $1.40 | |
| Shares (Basic) | 193,147,000 | 194,545,000 | 194,219,000 | -387,556,000 | 193,822,000 | 193,796,000 | 193,758,000 | -399,244,000 | 198,260,000 | 199,406,000 | 200,081,000 | -406,186,000 | 202,349,000 | 202,316,000 | 204,032,000 | -418,212,000 | |
| Shares (Diluted) | 193,944,000 | 195,383,000 | 195,319,000 | -390,298,000 | 195,230,000 | 195,094,000 | 195,188,000 | -402,777,000 | 200,047,000 | 201,177,000 | 201,837,000 | -410,367,000 | 204,375,000 | 204,256,000 | 206,327,000 | -423,687,000 | |
| EBITDA | $1.39B | $1.39B | $1.02B | · | $868M | $1.04B | $706M | · | $672M | $553M | $823M | · | $670M | $561M | $633M | · |
대차대조표 27
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.82B | $2.18B | $1.75B | $4.36B | $2.23B | $1.98B | $3.22B | $3.13B | $3.31B | $2.07B | $2.87B | $2.59B | $1.39B | $1.54B | $1.69B | $3.39B | |
| Receivables | $25.45B | $24.89B | $25.98B | $25.23B | $24.56B | $23.72B | $24.55B | $23.87B | $24.05B | $22.64B | $21.58B | · | $20.80B | $19.49B | $18.63B | · | |
| Inventory | $21.03B | $20.01B | $24.08B | $20.49B | $20.14B | $18.97B | $20.51B | $19.00B | $18.30B | $17.63B | $18.65B | · | $16.85B | $16.96B | $16.78B | · | |
| Prepaid Expense | $636M | $637M | $678M | $539M | $451M | $575M | $516M | $539M | $460M | $512M | $493M | · | $493M | $488M | $1.99B | · | |
| Current Assets | $55.34B | $53.14B | $54.15B | $52.24B | $48.81B | $46.53B | $49.99B | $47.72B | $47.31B | $44.16B | $44.86B | · | $40.99B | $39.99B | $40.71B | · | |
| PP&E (Net) | $2.84B | $2.81B | $2.45B | $2.54B | $2.43B | $2.30B | $2.10B | $2.18B | $2.08B | $2.09B | $2.12B | · | $2.15B | $2.15B | $2.14B | · | |
| PP&E (Gross) | · | · | · | $5.73B | · | · | · | $5.22B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | · | $3.19B | · | · | · | $3.03B | · | · | · | · | · | · | · | · | |
| Goodwill | $16.52B | $16.45B | $13.73B | $13.68B | $14.33B | $14.09B | $9.18B | $9.32B | $9.61B | $9.62B | $9.66B | $9.57B | $9.66B | $9.63B | $8.60B | $8.50B | |
| Intangibles | $5.93B | $6.05B | $3.68B | $3.77B | $3.93B | $3.86B | $3.68B | $4.00B | $4.01B | $4.18B | $4.38B | · | $4.77B | $4.88B | $4.43B | · | |
| Other Non-current Assets | $3.01B | $3.01B | $4.14B | $4.15B | $4.23B | $4.17B | $3.89B | $3.64B | $3.53B | $3.57B | $3.46B | · | $3.40B | $1.88B | $1.80B | · | |
| Total Assets | $83.81B | $81.65B | $78.36B | $76.59B | $73.96B | $71.19B | $69.05B | $67.10B | $66.77B | $63.87B | $64.69B | · | $61.18B | $58.77B | $57.91B | · | |
| Accounts Payable | $54.70B | $51.88B | $56.06B | $54.72B | $51.04B | $50.11B | $49.91B | $50.94B | $49.88B | $46.32B | $47.74B | · | $43.75B | $42.73B | $41.76B | · | |
| Accrued Liabilities | $3.35B | $3.20B | $2.73B | $2.98B | $2.72B | $2.45B | $2.39B | $2.76B | $2.53B | $2.37B | $2.44B | · | $2.17B | $2.07B | $2.01B | · | |
| Current Liabilities | $59.20B | $56.13B | $59.13B | $57.82B | $53.96B | $53.33B | $54.51B | $54.28B | $52.97B | $49.76B | $50.77B | · | $46.78B | $45.07B | $44.76B | · | |
| Capital Leases | · | · | · | $1.42B | · | · | · | $1.03B | · | · | · | · | · | · | · | · | |
| Deferred Tax | $1.79B | $1.75B | $1.64B | $1.62B | $1.61B | $1.62B | $1.59B | $1.64B | $1.61B | $1.70B | $1.69B | · | $1.72B | $1.74B | $1.63B | · | |
| Other Non-current Liabilities | $3.97B | $3.79B | $3.70B | $3.64B | $3.54B | $3.42B | $2.06B | $1.99B | $1.93B | $1.96B | $1.91B | · | $1.86B | $1.06B | $992M | · | |
| Long-term Debt | $11.72B | $12.39B | $7.92B | $7.66B | $8.24B | $7.86B | $8.15B | $4.39B | $4.73B | $5.25B | $4.78B | · | · | · | · | · | |
| Total Debt | $11.44B | $12.18B | $7.58B | · | $8.04B | $7.09B | $5.94B | · | $4.17B | $4.18B | $4.19B | · | $4.16B | $4.67B | $4.66B | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | |
| Retained Earnings | $9.14B | $8.49B | $6.97B | $6.53B | $6.98B | $6.40B | $5.79B | $5.42B | $5.51B | $5.13B | $4.82B | · | $4.07B | $3.69B | $3.36B | · | |
| Treasury Stock | $11.45B | $10.44B | $10.43B | $10.33B | $10.33B | $10.33B | $10.28B | $9.82B | $9.30B | $8.75B | $8.69B | · | $7.97B | $7.87B | $7.86B | · | |
| AOCI | $-980M | $-961M | $-905M | $-901M | $-844M | $-1.20B | $-1.40B | $-989M | $-1.28B | $-1.26B | $-1.14B | · | $-1.23B | $-1.32B | $-1.41B | · | |
| Stockholders' Equity | $3.05B | $3.40B | $1.91B | $1.51B | $1.98B | $1.01B | $227M | $646M | $925M | $1.08B | $912M | · | $686M | $282M | $-178M | · | |
| Liabilities + Equity | $83.81B | $81.65B | $78.36B | $76.59B | $73.96B | $71.19B | $69.05B | $67.10B | $66.77B | $63.87B | $64.69B | · | $61.18B | $58.77B | $57.91B | · | |
| Shares Outstanding | 190,826,409 | 194,560,641 | 194,521,885 | 193,937,673 | 193,860,959 | 193,783,768 | 193,849,411 | 194,943,968 | 197,008,633 | 199,388,633 | 199,461,864 | · | 202,109,227 | 202,410,686 | 202,225,546 | · |
현금 흐름 17
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $269M | $249M | $260M | $259M | $254M | $260M | $278M | · | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $29M | $28M | $66M | $26M | $23M | $28M | $70M | $35M | $22M | $28M | $63M | $25M | $21M | $23M | $56M | $16M | |
| Deferred Tax | $55M | $178M | $14M | $55M | $-17M | $26M | $-5M | $4M | $-70M | $-40M | $3M | $-29M | $-28M | $-49M | $-12M | $139M | |
| Amort. of Intangibles | $119M | $117M | $126M | $127M | $126M | $138M | $166M | $167M | $165M | $166M | $166M | $171M | $170M | $141M | $72M | $73M | |
| Restructuring | $61M | $41M | $14M | $89M | $42M | $53M | $46M | $81M | $42M | $76M | $34M | $52M | $64M | $97M | $16M | $-146M | |
| Other Non-cash | · | · | $-3.21B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $2.65B | $1.34B | $-2.31B | $3.13B | $109M | $3.35B | $-2.72B | $1.00B | $2.48B | $-878M | $885M | $1.83B | $745M | $630M | $710M | $1.16B | |
| CapEx | $226M | $166M | $119M | $250M | $183M | $129M | $106M | $182M | $118M | $113M | $74M | $175M | $104M | $103M | $76M | $174M | |
| Investing Cash Flow | $-240M | $-4.87B | $-299M | $-322M | $-235M | $-4.08B | $-343M | $-242M | $-144M | $-166M | $-66M | $-183M | $-819M | $-89M | $-1.51B | $-175M | |
| Debt Issued | · | · | · | · | · | · | · | · | $53M | $545M | $90M | · | $89M | $13M | $55M | · | |
| Net Debt Issued | · | · | $-132M | · | · | · | $-45M | · | · | · | $6M | · | · | · | $2M | · | |
| Stock Repurchased | · | · | · | $71.0K | $0 | $50M | $385M | $505M | $550M | $51M | $386M | $274M | $100M | $0 | $807M | $235M | |
| Net Stock Activity | · | · | · | · | · | · | $-385M | · | · | · | $-386M | · | · | · | $-807M | · | |
| Dividends Paid | $117M | $117M | $127M | $108M | $107M | $111M | $111M | $101M | $103M | $107M | $106M | $98M | $99M | $102M | $100M | $96M | |
| Financing Cash Flow | $-1.77B | $3.98B | $43M | $-684M | $215M | $-492M | $3.21B | $-957M | $-1.15B | $323M | $-552M | $-407M | $-82M | $-769M | $-964M | $-673M | |
| Net Change in Cash | $629M | $428M | $-2.59B | $2.12B | $97M | $-1.22B | $97M | $-179M | $1.19B | $-751M | $283M | $1.20B | $-140M | $-224M | $-1.68B | $291M | |
| Free Cash Flow | · | · | $-2.42B | · | · | · | $-2.82B | · | · | · | $811M | · | · | · | $634M | · |
수익성 8
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 4.3% | 4.6% | 3.6% | · | 3.6% | 4.1% | 3.1% | · | 3.2% | 3.7% | 3.4% | · | 3.4% | 3.6% | 3.4% | · | |
| Operating Margin | 1.3% | 1.5% | 0.88% | · | 1.1% | 1.4% | 0.87% | · | 0.91% | 0.81% | 1.1% | · | 1.0% | 0.88% | 1.0% | · | |
| Net Margin | 0.90% | 2.1% | 0.65% | · | 0.85% | 0.95% | 0.60% | · | 0.65% | 0.62% | 0.83% | · | 0.72% | 0.69% | 0.76% | · | |
| Pretax Margin | 1.2% | 2.7% | 0.82% | · | 1.1% | 1.2% | 0.76% | · | 0.85% | 0.68% | 1.1% | · | 0.91% | 0.81% | 0.94% | · | |
| EBITDA Margin | 1.6% | 1.8% | 1.2% | · | 1.1% | 1.4% | 0.87% | · | 0.91% | 0.81% | 1.1% | · | 1.0% | 0.88% | 1.0% | · | |
| ROA | 0.97% | 2.1% | 0.76% | · | 0.98% | 1.1% | 0.73% | · | 0.76% | 0.69% | 0.98% | · | 0.81% | 0.75% | 0.83% | · | |
| ROE | 30.3% | 74.4% | 52.4% | · | 47.3% | 68.5% | 85.9% | · | 60.0% | 61.7% | 164.0% | · | 105.4% | 104.7% | 1513.0% | · | |
| ROIC | 6.0% | 5.7% | 6.4% | · | 6.7% | 9.9% | 9.1% | · | 10.2% | 9.5% | 12.4% | · | 10.9% | 9.5% | 11.3% | · |
유동성 및 지급능력 4
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | |
| Quick Ratio | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | |
| Debt / Equity | 3.8 | 3.6 | 4.0 | · | 4.1 | 7.0 | 26.2 | · | 4.5 | 3.9 | 4.6 | · | 6.1 | 16.6 | -26.1 | · | |
| LT Debt / Equity | 3.8 | 3.6 | 4.0 | · | 4.1 | 7.0 | 26.2 | · | 4.5 | 3.9 | 4.6 | · | 6.1 | 16.6 | -26.1 | · |
효율성 3
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.1 | 1.2 | · | 1.1 | 1.1 | 1.1 | · | |
| Inventory Turnover | 3.9 | 3.8 | 3.7 | · | 4.0 | 4.0 | 4.0 | · | 4.1 | 3.8 | 3.9 | · | 4.0 | 3.8 | 3.7 | · | |
| Receivables Turnover | 3.4 | 3.2 | 3.4 | · | 3.3 | 3.3 | 3.5 | · | 3.3 | 3.2 | 3.6 | · | 3.4 | 3.4 | 3.5 | · |
가치 평가 (TTM) 14
| 지표 | 추세 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $329.71B | $320.41B | $323.54B | · | $311.85B | $299.60B | $296.40B | · | $281.86B | $271.07B | $265.50B | · | $253.32B | $244.09B | $240.26B | · | |
| Net Income TTM | $3.65B | $3.61B | $2.45B | · | $2.38B | $2.11B | $1.99B | · | $1.99B | $1.94B | $2.00B | · | $1.80B | $1.87B | $1.88B | · | |
| Market Cap | $54.00B | $61.12B | $65.70B | · | $58.13B | $53.89B | $43.55B | · | $44.39B | $48.45B | $40.97B | · | $38.89B | $32.41B | $33.51B | · | |
| Enterprise Value | $62.63B | $71.13B | $71.53B | · | $63.94B | $59.00B | $46.27B | · | $45.25B | $50.56B | $42.28B | · | $41.66B | $35.54B | $36.47B | · | |
| P/E | 15.1 | 17.0 | 26.9 | · | 24.7 | 26.0 | 22.5 | · | 22.9 | 25.4 | 21.0 | · | 22.0 | 17.8 | 18.5 | · | |
| P/S | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.1 | 0.1 | · | |
| P/B | 17.7 | 18.0 | 34.4 | · | 29.4 | 53.2 | 192.2 | · | 48.0 | 44.7 | 44.9 | · | 56.7 | 115.0 | -188.1 | · | |
| P / Cash Flow | · | · | -28.5 | · | · | · | -16.0 | · | · | · | 46.3 | · | · | · | 47.2 | · | |
| P / FCF | · | · | -27.1 | · | · | · | -15.4 | · | · | · | 50.5 | · | · | · | 52.8 | · | |
| EV / EBITDA | 45.1 | 51.1 | 70.1 | · | 73.7 | 56.9 | 65.5 | · | 67.3 | 91.4 | 51.4 | · | 62.2 | 63.4 | 57.6 | · | |
| EV / FCF | · | · | -29.5 | · | · | · | -16.4 | · | · | · | 52.1 | · | · | · | 57.5 | · | |
| EV / Revenue | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.1 | 0.2 | · | |
| Earnings Yield | 6.6% | 5.9% | 3.7% | · | 4.0% | 3.8% | 4.5% | · | 4.4% | 3.9% | 4.8% | · | 4.5% | 5.6% | 5.4% | · | |
| Payout Ratio | · | · | 22.6% | · | · | · | 22.7% | · | · | · | 17.6% | · | · | · | 20.8% | · |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | |
|---|---|---|---|---|---|
| 매출 | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B |
| 매출 총이익률 % | 3.6% | 3.4% | 3.4% | 3.5% | 3.2% |
| 영업이익률 % | 0.82% | 0.74% | 0.89% | 0.99% | 1.1% |
| 순이익 | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B |
| 희석 EPS | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 |
대차대조표
| 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 5.0 | 5.9 | 7.9 | -21.9 | 28.6 |
| 유동비율 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 |
| 당좌 비율 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
현금 흐름
| 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $3.21B | $3.00B | $3.45B | $2.21B | $2.23B |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 1,489개의 제출자 · $31.4B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 102 (-56 이전 분기 대비) | 172 (+41 이전 분기 대비) | 434 (-101 이전 분기 대비) | 595 (+65 이전 분기 대비) | +8.4M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3,502,993,290 | 12,378,943 | 11.15% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,719,934,713 | 9,611,756 | 8.66% | 주식 |
| STATE STREET CORP | $2,624,351,709 | 9,273,983 | 8.35% | 주식 |
| Walgreens Boots Alliance, Inc. | $2,240,779,050 | 7,473,000 | 7.13% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,358,112,555 | 4,819,419 | 4.32% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,231,165,897 | 4,350,717 | 3.92% | 주식 |
| FMR LLC | $850,228,724 | 3,004,554 | 2.71% | 주식 |
| NORGES BANK | $700,042,999 | 2,473,825 | 2.23% | 주식 |
| Capital Research Global Investors | $560,283,987 | 1,979,942 | 1.78% | 주식 |
| Carmignac Gestion | $494,462,712 | 1,747,363 | 1.57% | 주식 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $483,772,138 | 1,709,563 | 1.54% | 주식 |
| Mawer Investment Management Ltd. | $421,312,792 | 1,488,843 | 1.34% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $410,282,013 | 1,449,862 | 1.31% | 주식 |
| CITADEL ADVISORS LLC | $347,541,038 | 1,228,147 | 1.11% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $338,738,459 | 1,197,038 | 1.08% | 주식 |
| NEUBERGER BERMAN GROUP LLC | $315,929,430 | 1,116,828 | 1.01% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $313,668,332 | 1,108,447 | 1.00% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $313,605,793 | 1,108,226 | 1.00% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $294,327,781 | 1,040,101 | 0.94% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $293,610,144 | 1,037,565 | 0.93% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $268,966,547 | 950,479 | 0.86% | 주식 |
| LAZARD ASSET MANAGEMENT LLC | $261,088,180 | 922,638 | 0.83% | 주식 |
| Caisse de depot et placement du Quebec | $258,709,937 | 914,234 | 0.82% | 주식 |
| Boston Partners | $231,295,970 | 817,358 | 0.74% | 주식 |
| National Pension Service | $208,758,025 | 737,713 | 0.66% | 주식 |
| GOLDMAN SACHS GROUP INC | $208,660,680 | 737,369 | 0.66% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $205,281,694 | 653,472 | 0.65% | 주식 |
| NORDEA INVESTMENT MANAGEMENT AB | $180,668,066 | 644,564 | 0.58% | 주식 |
| Burgundy Asset Management Ltd. | $174,893,972 | 599,753 | 0.56% | 주식 |
| Balyasny Asset Management L.P. | $172,225,024 | 608,612 | 0.55% | 주식 |
| Point72 Asset Management, L.P. | $171,131,023 | 604,746 | 0.54% | 주식 |
| Assenagon Asset Management S.A. | $166,084,924 | 586,914 | 0.53% | 주식 |
| Squarepoint Ops LLC | $154,024,599 | 544,295 | 0.49% | 주식 |
| Swiss National Bank | $147,506,155 | 521,260 | 0.47% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $141,101,751 | 498,628 | 0.45% | 주식 |
| Swedbank AB | $134,859,213 | 476,568 | 0.43% | 주식 |
| TimesSquare Capital Management, LLC | $132,589,070 | 422,070 | 0.42% | 주식 |
| Legal & General Group Plc | $129,674,734 | 458,247 | 0.41% | 주식 |
| RHUMBLINE ADVISERS | $123,138,883 | 435,151 | 0.39% | 주식 |
| Vanguard Global Advisers, LLC | $120,449,305 | 425,646 | 0.38% | 주식 |
| BlackRock, Inc. | $119,463,969 | 422,164 | 0.38% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $117,740,633 | 416,074 | 0.37% | 주식 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $113,208,499 | 400,058 | 0.36% | 주식 |
| California Public Employees Retirement System | $110,655,367 | 391,036 | 0.35% | 주식 |
| BANK OF AMERICA CORP /DE/ | $105,342,134 | 372,260 | 0.34% | 주식 |
| SEB Asset Management AB | $104,030,095 | 367,624 | 0.33% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $101,511,435 | 358,723 | 0.32% | 주식 |
| VANGUARD GROUP INC | $100,694,421 | 298,133 | 0.32% | 주식 |
| Walleye Capital LLC | $98,419,595 | 347,797 | 0.31% | 주식 |
| MIZUHO MARKETS AMERICAS LLC | $96,213,200 | 340,000 | 0.31% | 주식 |
| JOHNSON INVESTMENT COUNSEL INC | $93,893,214 | 331,802 | 0.30% | 주식 |
| STOREBRAND ASSET MANAGEMENT AS | $93,049,484 | 328,820 | 0.30% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $88,657,847 | 282,224 | 0.28% | 주식 |
| Cornerstone Investment Partners, LLC | $86,260,510 | 304,829 | 0.27% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $85,771,238 | 303,100 | 0.27% | 콜 옵션 |
| JONES FINANCIAL COMPANIES LLLP | $85,147,559 | 297,583 | 0.27% | 주식 |
| CIBC Private Wealth Group LLC | $83,133,772 | 266,003 | 0.26% | 주식 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $81,593,038 | 288,335 | 0.26% | 주식 |
| FIL Ltd | $79,588,408 | 281,251 | 0.25% | 주식 |
| LPL Financial LLC | $76,804,992 | 271,415 | 0.24% | 주식 |
| TD Asset Management Inc | $76,770,210 | 271,292 | 0.24% | 주식 |
| BANK OF MONTREAL /CAN/ | $70,057,359 | 247,570 | 0.22% | 주식 |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $69,812,864 | 246,706 | 0.22% | 주식 |
| PRINCIPAL FINANCIAL GROUP INC | $68,792,155 | 243,099 | 0.22% | 주식 |
| CITADEL ADVISORS LLC | $68,622,650 | 242,500 | 0.22% | 콜 옵션 |
| FIRST MANHATTAN CO. LLC. | $68,126,586 | 240,747 | 0.22% | 주식 |
| AMERIPRISE FINANCIAL INC | $67,675,233 | 239,152 | 0.22% | 주식 |
| TREMBLANT CAPITAL GROUP | $67,203,788 | 237,486 | 0.21% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $64,886,066 | 229,296 | 0.21% | 주식 |
| EARNEST PARTNERS LLC | $63,127,461 | 223,081 | 0.20% | 주식 |
| FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | $60,624,220 | 214,235 | 0.19% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $60,395,855 | 213,428 | 0.19% | 주식 |
| JENNISON ASSOCIATES LLC | $60,017,829 | 212,092 | 0.19% | 주식 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $59,924,694 | 211,763 | 0.19% | 주식 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $57,032,921 | 201,544 | 0.18% | 주식 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $52,864,060 | 186,812 | 0.17% | 주식 |
| BARCLAYS PLC | $51,304,557 | 181,301 | 0.16% | 주식 |
| Mitsubishi UFJ Trust & Banking Corp | $51,082,984 | 180,518 | 0.16% | 주식 |
| PFA Pension, Forsikringsaktieselskab | $50,217,651 | 177,460 | 0.16% | 주식 |
| MARSHALL WACE, LLP | $50,044,447 | 176,848 | 0.16% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $49,878,621 | 176,262 | 0.16% | 주식 |
| Sio Capital Management, LLC | $49,121,932 | 173,588 | 0.16% | 주식 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $48,634,175 | 162,136 | 0.15% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $48,419,177 | 171,284 | 0.15% | 주식 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $47,513,047 | 151,248 | 0.15% | 주식 |
| AVIVA PLC | $47,242,096 | 166,945 | 0.15% | 주식 |
| Jefferies Financial Group Inc. | $46,356,935 | 163,817 | 0.15% | 주식 |
| Brandywine Global Investment Management, LLC | $45,181,831 | 133,773 | 0.14% | 주식 |
| Asset Management One Co., Ltd. | $44,176,566 | 140,627 | 0.14% | 주식 |
| Trajan Wealth LLC | $43,325,888 | 153,106 | 0.14% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $43,248,965 | 152,834 | 0.14% | 주식 |
| Ensign Peak Advisors, Inc | $42,869,206 | 151,492 | 0.14% | 주식 |
| CANADA PENSION PLAN INVESTMENT BOARD | $42,457,470 | 150,037 | 0.14% | 주식 |
| UBS Group AG | $41,937,353 | 148,199 | 0.13% | 주식 |
| Freestone Grove Partners LP | $41,195,379 | 145,577 | 0.13% | 주식 |
| Qube Research & Technologies Ltd | $40,558,109 | 143,325 | 0.13% | 주식 |
| VAN ECK ASSOCIATES CORP | $40,356,344 | 142,612 | 0.13% | 주식 |
| MACKENZIE FINANCIAL CORP | $40,057,234 | 141,555 | 0.13% | 주식 |
| DONALDSON CAPITAL MANAGEMENT, LLC | $38,839,791 | 137,253 | 0.12% | 주식 |
| ROYAL BANK OF CANADA | $37,959,000 | 134,139 | 0.12% | 주식 |
회사 내부자 49 명의 내부자 · 23 임원 · 27 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | President & CEO | 2025년 6월 18일 M | 44,094 | 0 | 0 | $0 |
| David R Yost | CEO | 2011년 5월 17일 M | 1,530,341 | 0 | 0 | $0 |
| Eva C Boratto | Chief Financial Officer | 2026년 6월 29일 A | — | 0 | 0 | $0 |
| Tim G. Guttman | Chief Financial Officer | 2018년 11월 9일 M | 53,505 | 0 | 0 | $0 |
| Michael D Dicandilo | Executive VP & CFO | 2011년 5월 2일 M | 89,698 | 0 | 0 | $0 |
| Kurt J Hilzinger | President & COO | 2007년 2월 15일 A | 176,400 | 0 | 0 | $0 |
| Elizabeth S Campbell | Executive Vice President | 2026년 6월 30일 A | 30,756 | 0 | 0 | $0 |
| Silvana Battaglia | Executive Vice President | 2026년 6월 30일 A | 23,624 | 0 | 0 | $0 |
| Steven H Collis | Executive Chairman | 2025년 9월 16일 M | 305,913 | 0 | 2 | $-13,314,729 |
| Lazarus Krikorian | SVP & Chief Accounting Officer | 2025년 5월 29일 S | 17,154 | 0 | 0 | $0 |
| Leslie E Donato | EVP & Chief Strategy Officer | 2024년 6월 28일 A | 9,525 | 0 | 0 | $0 |
| Gina Clark | Executive Vice President | 2024년 5월 31일 S | 13,284 | 0 | 0 | $0 |
| John G. Chou | Executive Vice President | 2021년 12월 20일 G | 81,367 | 0 | 0 | $0 |
| Kathy H. Gaddes | Executive Vice President | 2020년 2월 21일 M | 6,906 | 0 | 0 | $0 |
| Dale Danilewitz | Executive Vice President | 2019년 5월 23일 S | 1,085 | 0 | 0 | $0 |
| Howell Peyton R | Executive Vice President | 2018년 4월 4일 M | 47,989 | 0 | 0 | $0 |
| Sun Park | Executive Vice President | 2017년 11월 17일 F | 3,010 | 0 | 0 | $0 |
| James Frary | Executive Vice President | 2016년 11월 9일 A | 34,195 | 0 | 0 | $0 |
| Lawrence Marsh | Executive Vice President | 2016년 4월 29일 F | 8,897 | 0 | 0 | $0 |
| David W Neu | Executive Vice President | 2015년 11월 13일 F | 5,224 | 0 | 0 | $0 |
| June Barry | Executive Vice President | 2015년 11월 13일 M | 4,068 | 0 | 0 | $0 |
| Jeanne B. Fisher | Senior Vice President | 2010년 2월 1일 M | 27,190 | 0 | 0 | $0 |
| Terrance P Haas | Senior Vice President | 2008년 2월 27일 A | 25,728 | 0 | 0 | $0 |
| Lauren M Tyler | 이사 | 2026년 7월 31일 A | 4,456 | 1 | 0 | $148,626 |
| Dennis M Nally | 이사 | 2026년 7월 31일 A | 13,188 | 0 | 0 | $0 |
| Ellen Cooper | 이사 | 2026년 7월 31일 A | 893 | 0 | 0 | $0 |
| Dermot Mark Durcan | 이사 | 2026년 6월 18일 P | 31,767 | 2 | 0 | $2,161,800 |
| Lori Ryerkerk | 이사 | 2025년 7월 1일 A | 516 | 0 | 0 | $0 |
| Werner Baumann | 이사 | 2025년 5월 1일 A | 2,896 | 0 | 0 | $0 |
| Redonda Miller | 이사 | 2025년 3월 6일 A | 3,194 | 0 | 0 | $0 |
| Frank Clyburn | 이사 | 2025년 3월 6일 A | 1,157 | 0 | 0 | $0 |
| Lorence H. Kim | 이사 | 2025년 3월 6일 A | 3,524 | 0 | 0 | $0 |
| Richard W Gochnauer | 이사 | 2024년 3월 11일 M | 28,762 | 0 | 0 | $0 |
| Kathleen W Hyle | 이사 | 2024년 3월 11일 M | 24,406 | 0 | 0 | $0 |
| Henry Wadsworth Mcgee III | 이사 | 2023년 3월 9일 A | 20,479 | 0 | 0 | $0 |
| Jane E Henney MD | 이사 | 2023년 3월 5일 M | 24,685 | 0 | 0 | $0 |
| Michael J Long | 이사 | 2023년 3월 5일 M | 17,724 | 0 | 0 | $0 |
| Douglas R Conant | 이사 | 2019년 3월 4일 M | 8,062 | 0 | 0 | $0 |
| Richard C Gozon | 이사 | 2016년 2월 29일 M | 51,484 | 0 | 0 | $0 |
| Edward E Hagenlocker | 이사 | 2015년 3월 2일 M | 3,351 | 0 | 0 | $0 |
| Charles H Cotros | 이사 | 2012년 12월 7일 M | 26,773 | 0 | 0 | $0 |
| Lawrence J Wilson | 이사 | 2009년 5월 1일 A | 35,942 | 0 | 0 | $0 |
| Rodney H Brady | 이사 | 2007년 2월 19일 A | 52,746 | 0 | 0 | $0 |
| James R Mellor | 이사 | 2006년 1월 3일 M | 32,246 | 0 | 0 | $0 |
| Robert E Martini | 이사 | 2004년 1월 23일 G | 1,602,739 | 0 | 0 | $0 |
| Francis G Rodgers | 이사 | 2003년 11월 3일 A | 7,918 | 0 | 0 | $0 |
| AMERISOURCEBERGEN CORP | 10% 소유주 | 2007년 7월 31일 J | 0 | 0 | 0 | $0 |
| James F Cleary | — | 2026년 3월 11일 M | 160,357 | 0 | 0 | $0 |
| Lon R Greenberg | — | 2026년 3월 5일 A | 18,408 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 3 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Walgreens Boots Alliance Holdings LLC, WBA Investments, Inc., Walgreens Boots Alliance, Inc. ×21 제출 서류 | 2025년 6월 9일 | 4.96% | 수정본 | — | SEC |
| AB Acquisitions Holdings Limited, Alliance Santé Participations S.A., NEWCIP S.A., Stefano Pessina, KKR Sprint (2006) Limited, KKR 2006 Fund (Overseas), Limited Partnership, KKR Associates 2006 (Overseas), Limited Partnership, KKR 2006 Limited, KKR Sprint (European II) Limited, KKR European Fund II, Limited Partnership, KKR Associates Europe II, Limited Partnership, KKR Europe II Limited, KKR Sprint (KPE) Limited, KKR PEI Investments, L.P., KKR PEI Associates, L.P., KKR PEI GP Limited, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, Henry R. Kravis, George R. Roberts | 2015년 1월 23일 | — | 최초 제출 | — | SEC |
| WAB Holdings LLC, Walgreens Pharmacy Strategies, LLC, Bond Drug Company of Illinois, LLC, Walgreen Eastern Co., Inc., Walgreen Arizona Drug Co., Walgreen Hastings Co., Walgreen International Investments LLC, WBA Investments, LLC, Walgreen Co., Alliance Boots Luxembourg S.à r.l., Alliance Boots Holdings Limited, AB Acquisitions UK Holdco 7 Limited, AB Acquisitions Limited, Alliance Boots International Limited, Alliance Boots Limited, AB Acquisitions UK Topco Limited, AB Acquisitions Luxco 1 S.à r.l., Alliance Boots GmbH, Walgreen Swiss International GmbH, Ontario Holdings WBA Limited, Walgreen International S.à r.l., Superior Bermuda GP, Superior Luxco 3 S.à r.l., Walgreens Boots Alliance Scottish LP, WBA 1 Scottish LLP, Superior Luxco 2 S.à r.l., Superior Luxco 1 S.à r.l., Walgreen Investments Luxembourg SCS, Walgreen Investments Co, Walgreens Boots Alliance, Inc. ×2 제출 서류 | 2015년 1월 16일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 212 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| JMID · Janus Detroit Street Trust | 3.11% | 1,841 NS | 2026년 4월 30일 | N-PORT |
| IYK · iShares Trust | 2.76% | 121,004 SH | 2026년 8월 8일 | 일간 |
| FXG · First Trust Exchange-Traded AlphaDE… | 2.40% | 19,060 NS | 2026년 4월 30일 | N-PORT |
| PAWZ · ProShares Trust | 2.36% | 2,847 NS | 2026년 5월 31일 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 2.34% | 1,750 NS | 2026년 5월 31일 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 2.26% | 12,908 SH | 2026년 8월 8일 | 일간 |
| MEDI · Harbor ETF Trust | 2.16% | 1,935 NS | 2026년 4월 30일 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 1.91% | 186 NS | 2026년 4월 30일 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 1.83% | 568,607 SH | 2026년 8월 8일 | 일간 |
| SWP · Manager Directed Portfolios | 1.75% | 10,059 NS | 2026년 5월 31일 | N-PORT |
| IWP · iShares Trust | 1.73% | 1,079,322 SH | 2026년 8월 8일 | 일간 |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.72% | 42,128 SH | 2026년 8월 8일 | 일간 |
| QIDX · Spinnaker ETF Series | 1.66% | 2,065 NS | 2026년 4월 30일 | N-PORT |
| EPMB · Harbor ETF Trust | 1.56% | 228 NS | 2026년 4월 30일 | N-PORT |
| USMV · iShares Trust | 1.29% | 958,985 SH | 2026년 8월 8일 | 일간 |
| ESMV · iShares Trust | 1.27% | 308 SH | 2026년 8월 8일 | 일간 |
| UPSD · ETF Series Solutions | 1.21% | 3,966 NS | 2026년 4월 30일 | N-PORT |
| SRHQ · Elevation Series Trust | 1.17% | 7,354 NS | 2026년 4월 30일 | N-PORT |
| AMOM · Exchange Listed Funds Trust | 1.17% | 1,161 NS | 2026년 4월 30일 | N-PORT |
| ACWV · iShares, Inc. | 1.17% | 120,628 SH | 2026년 8월 8일 | 일간 |
| FMAG · FIDELITY COVINGTON TRUST | 1.10% | 9,066 NS | 2026년 4월 30일 | N-PORT |
| NULV · Nushares ETF Trust | 1.10% | 73,945 NS | 2026년 4월 30일 | N-PORT |
| COWZ · Pacer Funds Trust | 1.03% | 608,442 NS | 2026년 4월 30일 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.02% | 1,555 NS | 2026년 4월 30일 | N-PORT |
| GROZ · Zacks Trust | 0.93% | 3,136 NS | 2026년 5월 31일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.92% | 84,961 NS | 2026년 4월 30일 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0.90% | 1,187,313 SH | 2026년 8월 8일 | 일간 |
| CURE · Direxion Shares ETF Trust | 0.86% | 3,879 NS | 2026년 4월 30일 | N-PORT |
| RPV · Invesco Exchange-Traded Fund Trust | 0.85% | 45,117 SH | 2026년 8월 8일 | 일간 |
| IMCG · iShares Trust | 0.84% | 105,034 SH | 2026년 8월 8일 | 일간 |
| IXJ · iShares Trust | 0.80% | 102,068 SH | 2026년 8월 8일 | 일간 |
| ALTL · Pacer Funds Trust | 0.79% | 2,471 NS | 2026년 4월 30일 | N-PORT |
| JOET · Virtus ETF Trust II | 0.79% | 6,030 NS | 2026년 4월 30일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.77% | 555,571 SH | 2026년 8월 8일 | 일간 |
| PALC · Pacer Funds Trust | 0.76% | 5,696 NS | 2026년 4월 30일 | N-PORT |
| RXL · ProShares Trust | 0.76% | 2,029 NS | 2026년 5월 31일 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.75% | 285 NS | 2026년 5월 31일 | N-PORT |
| ROE · EA Series Trust | 0.73% | 7,012 NS | 2026년 5월 29일 | N-PORT |
| TAX · EA Series Trust | 0.72% | 680 NS | 2026년 5월 29일 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.68% | 342 NS | 2026년 4월 30일 | N-PORT |
| DUHP · Dimensional ETF Trust | 0.68% | 249,048 NS | 2026년 4월 30일 | N-PORT |
| SPVU · Invesco Exchange-Traded Fund Trust … | 0.66% | 3,314 NS | 2026년 5월 31일 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.63% | 18,623 SH | 2026년 8월 8일 | 일간 |
| VO · VANGUARD INDEX FUNDS | 0.50% | 4,005,623 SH | 2026년 8월 8일 | 일간 |
| QARP · DBX ETF Trust | 0.49% | 1,374 NS | 2026년 5월 29일 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 0.47% | 2,120 NS | 2026년 5월 31일 | N-PORT |
| RECS · Columbia ETF Trust I | 0.44% | 77,004 NS | 2026년 4월 30일 | N-PORT |
| IWR · iShares Trust | 0.43% | 760,297 SH | 2026년 8월 8일 | 일간 |
| IMCB · iShares Trust | 0.43% | 22,227 SH | 2026년 8월 8일 | 일간 |
| JSTC · Tidal Trust I | 0.40% | 4,993 NS | 2026년 5월 31일 | N-PORT |